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Abstract: Selective internal radiation therapy (SIRT) with microspheres labelled with the β-emitter 
yttrium-90 (Y-90) enables targeted delivery of radiation to hepatic tumors. SIRT is primarily used to treat 
inoperable primary or metastatic liver tumors. Eligible patients have usually been exposed to a variety of 
systemic anticancer therapies, including cytotoxic agents, targeted biologics, immunotherapy and peptide 
receptor radionuclide therapy (PRRT). All these treatments have potential interactions with SIRT; however, 
robust evidence on the safety of these potential combinations is lacking. This paper provides current 
clinical experiences and expert consensus guidelines for the use of SIRT in combination with the anticancer 
treatment agents likely to be encountered in clinical practice. It was agreed by the expert panel that 
precautions need to be taken with certain drugs, but that, in general, systemic therapies do not necessarily 
have to be stopped to perform SIRT. The authors recommend stopping vascular endothelial growth factor 
inhibitors 4–6 weeks before SIRT, and restart after the patient has recovered from the procedure. It may 
also be prudent to stop potent radiosensitizers such as gemcitabine therapy 4 weeks before SIRT, and restart 
treatment at least 2‒4 weeks later. Data from phase III studies combining SIRT with fluorouracil (5FU) 
or folinic acid/5FU/oxaliplatin (FOLFOX) suggest that hematological toxicity is more common from the 
combination than it is from chemotherapy without SIRT. There is no evidence to suggest that chemotherapy 
increases SIRT-specific gastro-intestinal or liver toxicities. 
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Introduction
Selective internal radiation therapy (SIRT) with resin or 
glass microspheres labelled with the β-emitter yttrium-90 
(Y-90) enables targeted delivery of radiation to inoperable 
primary or metastatic liver tumors (1-6). Most frequently 
used for the management of hepatocellular carcinoma 
(HCC) (5) and liver metastasis of colorectal cancer 
(mCRC) (7), SIRT has also been used to treat the primary 
liver tumor intrahepatic cholangiocarcinoma (ICC) (8), 
and liver metastasis of many other tumor types including 
neuroendocrine tumors (NETs) (9), breast cancer (10,11) 
and uveal melanoma (12,13).
In  HCC,  SIRT has  been e f fect ive  in  t reat ing 
intermediate [Barcelona Clinic Liver Cancer (BCLC) 
stage B] and advanced stages (BCLC stage C), with or 
without portal vein thrombosis (PVT). In mCRC, SIRT 
has been used at all stages of treatment including as salvage 
therapy in treatment-refractory disease (14,15), in second-
line settings (whether the switch occurred due to first-line 
toxicity or first-line treatment failure) (16,17), and in first-
line induction and maintenance settings (7,18). Likewise, in 
other tumor types, there is evidence that SIRT can be given 
at various stages (10,19-25).
Whereas stereotactic body radiotherapy delivers high 
doses of external radiation, SIRT provides a continuous dose 
of radiation inside the liver over a 14-day period (Figure 1). 
Since the Y-90-loaded microspheres preferentially localize 
in tumor arterial vasculature, very high radiation doses are 
delivered to tumors while maintaining tolerable radiation 
doses to normal hepatic tissue.
SIRT is administered to patients who have typically 
received systemic anticancer therapies. Subsets of patients 
will also receive these agents, concurrent with, or soon after 
the SIRT administration, all of which may interact with 
SIRT (Table 1). 
These include desirable radiation-sensitizing effects, 
along with the potential for adding to or intensifying 
expected SIRT-related adverse events (AEs) (Table 2). 
However, there are few large-scale, randomized clinical 
trials of SIRT that allow evidence-based guidance.
The SIRFLOX trial is the only large-scale randomized 
trial published to date of SIRT plus chemotherapy. It assessed 
the efficacy and safety of SIRT with 90 resin microspheres 
when combined with first-line mFOLFOX chemotherapy 
[5-fluorouracil (5FU), leucovorin and oxaliplatin] vs. 
mFOLFOX alone in patients with liver-only or liver-dominant 
mCRC (bevacizumab was also allowed at the discretion of 
the investigators) (7). The rationale for combining SIRT 
with these chemotherapeutic agents is partly based on the 
expectation that there would be a synergistic antitumor activity 
from combining fluoropyrimidine, oxaliplatin and radiation 
therapy (RT). The addition of 5FU/leucovorin to preoperative 
radiation improves local control in rectal cancer (33-35), but 
may also increase the rate of severe acute toxicity (33). The 
addition of oxaliplatin to a combination of RT and 5FU in 
patients undergoing surgery for rectal cancer also improved 
the pathologic complete response (pCR) rate from 13% to 
17% (P=0.038) (36). The feasibility of combining SIRT with 
first-line 5FU/leucovorin-based chemotherapy or FOLFOX 
chemotherapy for mCRC has been demonstrated in small-
scale studies (18,27,37,38), but a dose-limiting toxicity of 
grade 3/4 neutropenia led to modifying the oxaliplatin dose 
from 85 to 60 mg/m2 for the first three cycles of FOLFOX if 
SIRT was administered with cycle 1 (on day 3 or 4). Even with 
this modification to FOLFOX in the SIRT arm in SIRFLOX, 
neutropenia, febrile neutropenia, thrombocytopenia, fatigue 
and abdominal pain occurred at a significantly greater 
frequency in the arm receiving SIRT, but at a frequency 
and severity that was expected and manageable (7). 
No patient had a gastric/duodenal ulcer in the mFOLFOX 
arm but nine (3.7%) had this AE in the SIRT arm. 
Radiation hepatitis occurred in two (0.8%) patients 
receiving SIRT and was managed with low-molecular-
weight heparin, diuretics and corticosteroids, and hepatic 
failure occurred in 3 (1.2%) patients receiving SIRT (7). 
However, the influence of the oxaliplatin dose on the 














Figure 1 Continuous low-dose Y-90 radiation versus daily high-
dose SBRT. Y-90, yttrium 90; SBRT, stereotactic body radiotherapy.
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Table 1 Systemic therapies and their potential toxicities when combined with SIRT
Drug name





5FU Radiosensitization Liver toxicity Hendlisz et al. 2010 (14)/– No safety concerns
Capecitabine Radiosensitization Liver toxicity Cohen et al. 2014 (26)/– Capecitabine 1,000 mg/m2  




Radiosensitization Liver toxicity Sharma et al. 2007 (18)/
NCT02807181
Reduced dose as used in 
SIRFLOX
Irinotecan Radiosensitization Liver toxicity Gulec et al. 2014 (27), 
van Hazel et al.  
2009 (16)/–
Irinotecan 100 mg/m2 on 
days 1 and 8 of a 3-week 
cycle is recommended
TAS 102 Radiosensitization Liver toxicity –/NCT02602327 SCTb
Taxanes Radiosensitization Unknown Unknown Unknown
Gemcitabine Radiosensitization Unknown Iñarrairaegui et al. 2015 
(28)/NCT02807181
SCT
Octreotide Radiosensitization None Kennedy et al.  
2015 (29)/–
No safety concerns
Lanreotide Radiosensitization None –/NCT02859064 SCT
Temozolomide Radiosensitization Unknown Unknown Unknown
Inhibitors of tumor signalling pathways 
Sunitinib Increased dose delivered to 
healthy liver due to reduced 
tumor arterial blood flow and 
increased risk of GI hemorrhage
–/– –
Sorafenib Increased dose delivered to 
healthy liver due to reduced 
tumor arterial blood flow and 
increased risk of GI hemorrhage
Salman et al. 2016 (30)/
NCT01126645
No apparent safety 
concerns with regular dose
Regorafenib Increased dose delivered to 
healthy liver due to reduced 
tumor arterial blood flow and 
increased risk of GI hemorrhage
Kennedy et al.  
2017 (31)/–
Preliminary results show 
no safety concerns with 
sequential use
Bevacizumab Increased dose delivered to 
healthy liver due to reduced 
tumor arterial blood flow and 
increased risk of GI hemorrhage
van Hazel et al. 2016 (7)/– No apparent safety 
concerns with regular dose
Trastuzumab Liver toxicity –/– –
Table 1 (continued)
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These published data have been corroborated by the 
FOXFIRE-SIRFLOX-FOXFIRE Global combined 
analysis of 1,103 patients presented in abstract form (39). 
Despite improving objective response rate and liver-
specific progression, the addition of SIRT had no impact 
on overall survival (OS) and increased the frequency of 
grade 3–5 AEs (39). Therefore, this combination in first-
line treatment of metastatic colorectal cancer cannot be 
recommended by the expert panel.
A recent systematic review provided further guidance 
on the optimal approach to managing some of the most 
important complications of SIRT, and this guidance is 
central to managing these complications when they occur in 
the combination settings discussed here (40).
We met to reach consensus on combinations of systemic 
therapies and SIRT that are more likely to be encountered 
in current clinical practice than the first-line treatment of 
mCRC assessed in the FOXFIRE-SIRFLOX-FOXFIRE 
Global trials. We sought to investigate safety and practical 
considerations, grade the evidence, and provide guidance 
on the key considerations in management through a series 
of clinical scenarios (Table 2). Given the increased use of 
SIRT in multiple clinical settings, we developed this paper 
to provide clinical experience and consensus guidelines for 
its use with chemotherapy.
Methods
An international panel of experts, with extensive experience 
of using SIRT, from a range of disciplines, was convened 
in January 2017 to discuss a set of pre-formulated topics. 
Extensive literature searches were conducted on each topic: 
SIRT and cytotoxics; SIRT and biologics; SIRT and tyrosine 
kinase inhibitors (TKIs); SIRT and mechanistic target of 
Table 1 (continued)
Drug name









specific T cell 
response







specific T cell 
response







specific T cell 
response
Liver-directed autoimmunity NA/NCT03005002 SCT
CARc T cells Redirection of T cell 
effector functions
CRSd-induced hepatotoxicity NA/NCT02416466 SCT
a, National Clinical Trial; b, Subject to Clinical Trial; c, chimeric antigen receptor; d, cytokine release syndrome. SIRT, selective internal radiation 
therapy; GI, gastrointestinal; NA, not available/applicable; 5Fu, 5-fluorouracil; CRC, colorectal cancer.
Table 2 Adverse events associated with selective internal radiation 
therapy (32)




Postembolization syndrome requiring 
extended stay or readmission
1‒2
Death within 30 days 0‒2
Iatrogenic dissection preventing treatment 1
Radiation-induced skin injury <1
Radiation pneumonitis <1
Radiation-induced pulmonary fibrosis <1
Biloma requiring percutaneous drainage <1
Abscess with functional sphincter of Oddi <1
REILD,  radioembol izat ion- induced l iver  d isease;  GI , 
gastrointestinal.
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rapamycin (mTOR) inhibitors; SIRT and immunotherapy; 
and SIRT and peptide receptor radionuclide therapy 
(PRRT). In light of the evidence, the panel developed 
relevant clinical questions/scenarios to discuss the evidence 
and provide advice on best practice. These were discussed 
and modified until consensus was reached. If no consensus 
was achieved on a specific point, the alternative views of 
the group are described in this paper. An adapted version 
of the ‘Infectious Diseases Society of America-United 
States Public Health Service Grading System’ was used 
to define the level of evidence (LoE) and strength of each 
recommendation (41).
Recommendations
Clinical question 1: integration of SIRT pre-progression, 
after at least 4 months of first-line chemotherapy as a 
potential conversion or consolidation approach for mCRC
In a patient with the colorectal primary adenocarcinoma in 
place, large-volume and liver-dominant metastasis, who has 
received approximately 4 months of first-line chemotherapy 
and has had a response but is unlikely to be a candidate for 
resection with continued chemotherapy, and is exhibiting 
chemotherapy-induced neuropathy, what are the issues 
when considering SIRT?
Rationale and recommendations
First-line chemotherapy strategies have evolved rapidly and 
the concept of ‘lines’ of therapy for mCRC often merges 
into a continuum of care. A change of either the backbone 
(irinotecan versus oxaliplatin) or the biological agent 
[vascular endothelial growth factor (VEGF) inhibitor vs. 
epidermal growth factor receptor (EGFR) inhibitor], is used 
here as the distinction between changing from a first-line to 
a second-line strategy.
The maximum response of  mCRC to f irst- l ine 
chemotherapy is usually evident within 3–6 months of 
starting first-line chemotherapy (42), and if patients are 
not candidates for liver resection at this stage, further 
chemotherapy is unlikely to convert them to resectability. 
However, in one study of 1,104 patients with initially 
unresectable liver metastases of CRC, 12.5% became 
eligible for surgery, with 23% of these patients having 
undergone two or three lines of chemotherapy prior to 
resection (LoE V; grade C) (43). Following failure of first-
line chemotherapy for mCRC, the addition of an anti-
EGFR agent to second-line folinic acid, fluorouracil and 
irinotecan hydrochloride (FOLFIRI) in patients with wild-
type (WT) KRAS tumors led to an improvement in the 
response rate from 10% to 35% (44). Patients with liver 
dominant 5FU-refractory disease receiving SIRT combined 
with irinotecan also had an improved response rate of 
48% compared with 5–16% with irinotecan alone (16). 
However, administering additional cycles of combination 
chemotherapy beyond 4 months may result in decreased 
tolerance and increased toxicity.
The integration of SIRT following an initial ‘induction 
therapy’ phase may allow for a ‘treatment holiday’ from 
chemotherapy, or may have an additive or synergistic effect 
following radiosensitizing chemotherapy. Patients who 
have had an initial response to first-line chemotherapy but 
insufficient to make them candidates for resection, and 
who have chemotherapy-induced AEs, are often referred 
to a specialist center for SIRT. A preliminary report of 
23 patients with liver dominant mCRC who received Y-90 
resin microspheres 12–26 weeks (median 21 weeks) after 
starting first-line chemotherapy (oxaliplatin, 100%; 5FU, 
8.7%; or capecitabine, 91.3%; plus cetuximab, 60.9%; 
irinotecan, 21.7%; or bevacizumab, 8.7%) resulted in partial 
response or stable disease in 91.3% of cases, resection in 
13%, and no grade 3/4 AEs (45). Neuropathy is a common 
AE of oxaliplatin, (46) and it may lead to oxaliplatin 
withdrawal. In non-progressing cases, a maintenance 
approach (or de-escalation) such as with capecitabine plus 
bevacizumab may be recommended.
An ongoing trial (SIR-step; clinicaltrials.gov/ct2/
show/NCT01895257) aims to recruit 162 patients with 
stable mCRC after 3–6 months’ induction chemotherapy 
with FOLFOX, FOLFIRI or XELOX (with or without 
bevacizumab) who will be randomized to receive either 
maintenance chemotherapy or maintenance chemotherapy 
plus SIRT with Y-90 resin microspheres. 
Bevacizumab or other VEGF inhibitors may lead to 
‘pruning’ from vasoconstriction and/or fragility within the 
hepatic vasculature. This may result in vascular dissection of 
the hepatic arteries, which can prevent safe and/or effective 
delivery of subsequent of concomitant SIRT (Figure 2). 
In a worst-case scenario, injury to the fragile vessels can 
result in a pseudoaneurysm. Therefore, if bevacizumab is 
already used in the first-line regimen, these issues must 
be considered before performing SIRT. Bevacizumab has 
a half-life of approximately 20 days (47); therefore, it is 
recommended to stop bevacizumab 4–6 weeks before the 
SIRT procedure to reduce the potential issues of vascular 
pruning/dissection, and restart bevacizumab after the 
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Figure 2 Vascular injury related to biologic agents in colorectal cancer. This 70-year-old male had metastatic colorectal cancer that had 
progressed on first- and second-line therapies and was being treated with bevacizumab monotherapy at the time of treatment. His positron 
emission tomography/computed tomography scan demonstrated multiple hypermetabolic foci in the left and caudate lobes (A). Angiography 
was performed with the patient on bevacizumab. Celiac angiography was performed prior to and after advancing a catheter in the common 
hepatic artery (B, C). Following catheterization dissection flap (white arrow, C) extended from the common hepatic artery and the left 
lateral segment branches were occluded (thin arrow, B, C) along with the gastroduodenal artery (thick arrow, B, C). The patient was placed 
on clopidrogel in an attempt to avoid thrombosis of the hepatic artery and returned for another attempt to treat four weeks later. At that 
time (D), there was a large pseudoaneurysm (arrow, D) and the downstream arteries were attenuated, likely secondary to the underlying 
vascular injury. The pseudoaneurysm was embolized with coils (arrow, E) with resulting occlusion of the common hepatic artery (F). Several 
interventional radiologists were surveyed regarding the length of time from the last dose of bevacizumab that was considered safe to perform 
angiography. The consensus was 4 weeks from the date of the most recent dose with restarting 1–2 days after arteriography.
patient has recovered from the procedure. The optimal 
timing of SIRT administration could potentially be at the 
end of a 3–4-week chemotherapy treatment cycle, thus 
avoiding potentially deleterious treatment interruptions. 
In SIRFLOX, where SIRT was integrated early into first-
line chemotherapy, bevacizumab was withheld until at least 
cycle 4, and there was no evidence of any clinical detriment 
on progression-free survival (PFS) (7). This finding in the 
early first-line setting may give us confidence that delaying 
the introduction or re-introduction of bevacizumab will not 
have a negative effect in later settings.
The RAS/BRAF mutation status of the patient, and 
tumor location, appear to have prognostic value and predict 
the response to EGFR inhibitors and thus guide treatment 
decisions. At this stage, these biomarkers do not clearly 
inform the likely response to SIRT, due to lack of data.
Capecitabine, as a prodrug of 5FU, is a radiosensitizer. 
Based on limited data from studies, including a formal 
phase I study (26) and user experience, the consensus group 
concluded that capecitabine is safe to combine with SIRT in 
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a similar way to 5FU. As capecitabine dosing is frequently 
prolonged (e.g., 2 out of 3 weeks), the guidance from this 
consensus in the first-line setting is similar to the salvage 
setting because SIRT appears to be safely administered in 
the third or fourth week (at the end of a treatment cycle). 
Clinical question 2: using SIRT with second-line 
chemotherapy in mCRC
In a patient with the primary tumor in place and liver-
dominant metastasis, who has progressed after receiving 
first-line chemotherapy and is initiating second-line 
chemotherapy with FOLFIRI, is it safe to add SIRT?
Rationale and recommendations
As with the first clinical question, referrals for SIRT in the 
second-line setting are a frequent occurrence in clinical 
practice. 
In a large cohort study of 606 patients with mCRC 
receiving SIRT, 206 received SIRT in the second-line or 
later setting after 5FU and oxaliplatin-based chemotherapy. 
Overall, AE profiles were similar irrespective of the 
number of previous chemotherapy lines (48). Grade 3 
or greater GI ulcer was observed in 1.7% of patients 
and radioembolization-induced liver disease (REILD) 
was observed in 0.5%, but the relative safety of different 
chemotherapy/SIRT combinations was not assessed.
Other smaller scale studies assessed SIRT in various 
second-line settings. For example, in 25 patients with 
mCRC who were refractory to 5FU-based first-line 
chemotherapy (8 patients had failed subsequent lines of 
chemotherapy also), SIRT (during the first cycle) was 
combined with second-line irinotecan (at three different 
doses on days 1 and 8 of a 3-week cycle) (16). The safety 
profile of the combination was similar to that of irinotecan 
alone, with fewer myelosuppression AEs than previously 
observed with SIRT plus FOLFOX. A phase II study 
assessed the use of SIRT after oxaliplatin-based first-line 
chemotherapy and before second-line irinotecan-based 
chemotherapy, but limited data were released (49). Similar 
findings were reported in 72 patients who had received 
mostly oxaliplatin and 5FU-based chemotherapy (one or 
more lines), and SIRT with Y-90 glass microspheres (3). 
In clinical practice, a single whole liver treatment of 
SIRT or sequential lobar treatment via two sessions of SIRT 
4–8 weeks apart may be delivered. Therefore, to manage 
the timing of, for example, second-line chemotherapy 
and/or bevacizumab administration, it is necessary to 
map out a 4–8-week treatment plan. If bevacizumab is 
to be added, similar principles as discussed in question 
1 apply. In Europe, the use of biologics in the second-line 
setting is less frequent than in the USA, and FOLFIRI 
is often the preferred approach. Concurrent FOLFIRI 
and SIRT is considered a feasible approach; however, the 
timing of SIRT relative to second-line chemotherapy (at 
the start, in the middle of the chemotherapy course, or 
after all cycles of second-line chemotherapy have been 
administered) may depend on various factors such as the 
aim of treatment, patient fitness, and whether the metastasis 
is liver-dominant. Data are lacking for concomitant SIRT 
and FOLFIRI administration but giving SIRT on day 3 
or 4 of the first cycle may be feasible. The use of SIRT is 
less likely in the situation of non-liver-dominant disease. 
In a cohort study of 260 patients, it was found that REILD 
only occurred in patients who had cirrhosis or who had 
been exposed to prolonged chemotherapy (50). The type 
of chemotherapeutic agent did not impact on the incidence 
of REILD. Among non-cirrhotic patients in this study, 
exposure to chemotherapy in the 2 months following SIRT 
was an independent predictor of REILD [odds ratio (OR) 
=6.46; 95% CI, 1.60–25.91]. 
Other VEGF inhibitors or EGFR inhibitors may also be 
used in this setting. EGFR inhibitors are radiosensitizers, 
which may provide a rationale for their use with SIRT but 
also may increase the risk of radiation toxicity to normal 
liver parenchyma (LoE V). Anecdotal clinical experience 
suggests there are fewer issues regarding vascular injury 
during catheterization with these agents before SIRT 
than there are with bevacizumab, and that administration 
of SIRT at 2 weeks after the last dose of cetuximab or 
panitumumab is feasible. However, owing to the theoretical 
issue of EGF receptor saturation, these agents may not be 
cleared from hepatocytes as rapidly as expected from plasma 
half-life (51). High-quality data are lacking to support any 
recommendation, and the combination of EGFR inhibitors 
and SIRT must be carefully considered on a case-by-case 
basis. 
Clinical question 3: salvage settings in mCRC
In a patient who has progressive chemo-refractory mCRC 
and SIRT is being initiated, what are the considerations 
with respect to other treatments?
Rationale and recommendations
In chemorefractory disease, combining SIRT with 
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radiosensitizing chemotherapy may increase PFS compared 
with chemotherapy alone. While acute toxicity associated 
with SIRT may be transient and manageable in this setting, 
the impact of REILD or GI ulcers on the patient need to be 
considered.
One phase III trial assessed SIRT with Y-90 resin 
microspheres plus 5FU compared with 5FU alone in 
44 liver-limited mCRC patients refractory to previous 
chemotherapy. Time to liver progression and time to tumor 
progression were increased significantly with the addition 
of SIRT (LoE II; grade B) (14). There was no impact on 
OS, possibly due to control patients being allowed to cross 
over to SIRT at progression and the small sample size. 
There were fewer grade 3/4 toxicities in the patients given 
SIRT who also received a reduced 5FU dose (225 instead 
of 300 mg/m2) in the first cycle. Patients in this study may 
have failed multiple lines of chemotherapy (LoE I; grade A). 
Rather than 5FU infusion, some physicians may prefer to 
prescribe oral capecitabine. 
Capecitabine is an important treatment for GI cancers 
that is not endorsed by the National Comprehensive Cancer 
Network (NCCN) but is used in some community practices 
as a sole agent in later lines of chemotherapy for mCRC. If 
considering SIRT, it is important to decide whether SIRT 
is feasible with capecitabine or whether this agent should 
be withdrawn. Capecitabine is a radiosensitizer that has 
been combined with SIRT in two recent phase I studies. 
In 24 patients (17 with mCRC) a maximum tolerated 
dose of capecitabine (given for 14 days every 21 days) was 
not reached when combined with SIRT with Y-90 resin 
microspheres (given on day 2 of the first cycle) (26). The 
authors suggested that a capecitabine dose of 1,000 mg/m2 
bid be used in phase II studies. The combination of 
SIRT and capecitabine was well tolerated, with toxicities 
approximating those seen with either modality administered 
as monotherapy. Partial response or stable disease was 
observed in 87.5% of patients (LoE III; grade B) (26). In 
16 patients (9 with mCRC) given full-dose capecitabine 
(during days 1–14 of a 21-day cycle), SIRT with Y-90 glass 
microspheres was given at days 1–7 of the second cycle (52). 
A maximum tolerated dose for SIRT was not reached 
when doses up to 170 Gy were assessed (LoE III; grade C). 
There are no specific safety concerns regarding the co-
administration of SIRT and capecitabine, if doses do 
not exceed those used in the trials described here. In the 
absence of more robust data, some experts practise stopping 
all medication, regardless of the type of agent, for 2–4 weeks 
prior to SIRT.
Although several trials have demonstrated favorable 
outcomes with SIRT as monotherapy and together with 
concomitant chemotherapy in chemorefractory mCRC, 
the impact of adding chemotherapy to SIRT on survival 
in this setting has not been established. Some of the most 
encouraging results come from the combination of SIRT + 
5FU, which improved the median time to liver progression 
compared with 5FU alone in patients with liver-limited 
chemorefractory mCRC (5.5 vs. 2.1 months, respectively; 
P=0.003) (14). In a recent retrospective study of 27 patients 
with 5FU-refractory disease, SIRT with concurrent 
chemotherapy (5FU, capecitabine, irinotecan or FOLFOX) 
was associated with increased disease control rates (84% 
vs. 14% with SIRT alone; P=0.001), as well as prolonged 
liver PFS (176 vs. 91 days with SIRT alone; P=0.0009) (53). 
The median OS was numerically superior in the SIRT 
plus chemotherapy group (212 vs. 154 days with SIRT 
alone); but did not reach significance (P=0.1023). Toxicity 
profiles were similar between the SIRT and the SIRT plus 
chemotherapy arms. However, liver-only patients in the 
salvage setting are uncommon and chemotherapy may not 
be needed as a radiosensitizer per se, but can be added to try 
to control extrahepatic disease progression.
After failure on first- and second-line chemotherapy, 
cetuximab can produce favorable outcomes in RAS WT 
patients (Figure 3). With regard to sequencing cetuximab 
doses and SIRT, experts suggest waiting 2–4 weeks 
between the last dose of this EGFR inhibitor and the 
SIRT procedure. There are few data on how to sequence 
SIRT with regorafenib (being addressed in a formal phase 
I study) or TAS-102. The latter can cause prolonged 
myelosuppression and as such we have to be mindful of a 
potential interaction with SIRT.
Patients who are clinically unsuitable for SIRT in the 
salvage setting include those with extensive uncontrolled 
extrahepatic disease or abnormal liver function tests (54). 
Clinical question 4: advanced HCC receiving sorafenib
In a patient who has advanced HCC (Child-Pugh A/B), is it 
safe to combine SIRT with other therapies?
Rationale and recommendations
This type of patient constitutes the most frequent indication 
for SIRT in HCC, and combining SIRT with the TKI 
sorafenib may improve outcomes. Antiangiogenic agents 
have been shown to normalize the vessels and allow them 
to deliver oxygen more efficiently to tumors (55), which 
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may increase sensitivity to tumor-delivered radiation (56). 
However, a recent study in cell lines suggested no synergistic 
activity between sorafenib and Y-90 (57). Despite this, 
the possibility of using SIRT in patients already receiving 
sorafenib is encountered in clinical practice (Figure 4). 
For patients with advanced HCC, sorafenib is the current 
standard of care. Although there are limited data on the 
effect of combining SIRT with sorafenib, the safety profile 
does appear acceptable. A study of 20 patients with HCC 
(Child Pugh ≤B8, no vascular invasion) compared SIRT 
with Y-90 glass microspheres alone versus the combination 
of SIRT and sorafenib (treated with sorafenib 400 mg 
bid for 14 days before SIRT, with the intent to bridge to 
transplantation). The combination arm was associated 
with more peri-operative biliary complications than with 
SIRT alone (LoE III) (58). The ongoing SORAMIC study 
compares SIRT with Y-90 resin microspheres followed 
3 days later with oral sorafenib (200 mg bid for 1 week 
and then 400 mg bid) vs. sorafenib alone with a matching 
dosing schedule in patients with Child-Pugh ≤B7 BCLC A–
C class HCC. Initial safety results of 40 patients suggested 
similar AE profiles in both arms (LoE II) (59). A phase II 
study assessed the safety and efficacy of SIRT followed by 
the initiation of sorafenib therapy (400 mg bid) 14 days later 
in 29 patients with inoperable HCC (BCLC stage B or C; 
69% Child-Pugh A) (60). The response rate was promising 
(7% complete response; 18% partial response; 54% 
stable disease), and the AE profile was similar to sorafenib 
monotherapy (the most frequent grade 3 or higher AE was 
hand-foot syndrome; grade ≥3 hyperbilirubinemia was also 
A B C
D E F
Figure 3 Combination Y-90 SIRT and EGFR inhibitor in colorectal cancer. This 69-year-old male had metastatic colorectal cancer with 
progression on first-and second-line therapy. He was on cetuximab with progressive liver metastases in the right lobe of the liver (A-C). 
He was mapped 2 weeks after his most recent dose of cetuximab and treated with SIRT the week after mapping. His biologic agent was 
restarted two days after treatment. Reimaging one month after treatment (D-F) demonstrated extensive necrosis of his liver metastases. 
His carcinoembryonic antigen dropped from 77 to 4 μg/L. Several interventional radiologists were surveyed regarding the length of time 
from the last dose of an EGFR inhibitor to performing arteriography with intervention. There was less experience with these drugs than 
with bevacizumab and only three responses were given: two interventional radiologists preferred 4 weeks from the most recent dose and the 
third preferred 2 weeks from the most recent dose. All respondents mentioned they had much less experience with biologic drugs outside 
bevacizumab. Y-90, yttrium 90; SIRT, selective internal radiation therapy; EGFR, epidermal growth factor receptor.
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observed in three patients) (LoE III) (60). In a recent study 
of patients with unresectable BCLC A-C class HCC (82.5% 
were Child-Pugh A; >50% BCLC C), sorafenib 400 mg bid 
was administered for 6–8 weeks before SIRT with Y-90 glass 
microspheres. Sorafenib treatment was not interrupted and 
was continued after the SIRT procedure (30). The addition 
of SIRT did not appear to affect the expected toxicity profile 
from sorafenib (LoE III). 
There are no specific recommendations on the optimal 
timing of SIRT relative to sorafenib initiation. As with 
bevacizumab, there is a theoretical risk of damage to 
the large blood vessels, and there are anecdotal reports 
of pruning with the use of sorafenib in clinical practice. 
However, as sorafenib is a twice-daily oral therapy with a 
short half-life, such events can be managed with cessation 
of treatment for up to a week before the SIRT procedure. 
The cirrhotic liver appears to tolerate SIRT and the 
combination with sorafenib well (59). For low burden 
disease, the interventional radiologist should attempt to 
treat the smallest required volume of the liver. Additionally, 
maximal tumor vascularity will result in the greatest volume 
of Y-90 microspheres being delivered to the tumor. Intra-
arterial therapy + sorafenib is frequently performed for 
HCC with limited metastatic disease. A formal study 
focusing on consolidation therapy after several months of 
sorafenib to assess the impact on mortality, has not been 
performed. Regorafenib is now approved as a second-line 
treatment option after sorafenib failure, but there are few 
data on regorafenib and SIRT.
Clinical question 5: advanced HCC with lobar but not 
main PVT
How do outcomes with SIRT compare with standard of 
care sorafenib in patients with advanced HCC?
Rationale and recommendations
Although sorafenib is generally recommended for the 
management of HCC with PVT, it provides only minor 
improvements in OS and low response rates in this group of 
patients (61,62). Given the tolerability of SIRT in patients 
with compensated liver disease and the lack of an embolic 
effect, SIRT is used in many clinical situations for advanced 
HCC (BCLC stage C) (Figure 5). One potential advantage 
of this approach is keeping sorafenib as a second-line 
therapy when extrahepatic disease occurs. 
In a review of treatment regimens selected for 
1,717 HCC patients in Korea, 608 BCLC stage C 
patients were identified (63). Only 36 patients (4.3%) 
received sorafenib. When time to progression and OS are 
compared directly, outcomes with sorafenib and SIRT for 
advanced HCC were similar. More recently, the initial 
report from the randomized SARAH trial also suggested 
similar efficacy of SIRT and sorafenib (median OS 8.0 and 
9.9 months in the SIRT and sorafenib groups, respectively, 
P=0.179), but with patients receiving SIRT having a better 
A B C
Figure 4 Combination of Y-90 SIRT and sorafenib for Barcelona clinic liver cancer stage C hepatocellular carcinoma. This 55-year-old 
female was treated with chemoembolization at an outside institution and referred with a 14 cm HCC invading the hepatic vein on cross 
sectional imaging. (A) Demonstrates a small amount of central necrosis including lipiodol from the chemoembolization. (B) Reveals the 
tumor thrombus extending into the hepatic vein confluence into the right atrium (arrow). She was initiated on sorafenib and referred for 
intra-arterial therapy at our institution. After performing Y-90 SIRT, there was extensive response with follow-up imaging (C) demonstrating 
extensive tumor necrosis with minimal residual enhancement and maximal diameter of 10 cm. Y-90, yttrium 90; SIRT, selective internal 
radiation therapy; HCC, hepatocellular carcinoma.
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quality of life and experiencing fewer AEs than patients 
receiving sorafenib (82 and 111 treatment-related serious 
AEs, respectively). Objective response rate was 19.0% and 
11.6% (P=0.042) with SIRT and sorafenib, respectively (64). 
SIRveNIB, with a similar design and patient eligibility to 
SARAH but conducted in South-East Asia, reported a very 
similar result (65).
When considering locoregional therapies in the setting 
of PVT, performance status and level of venous occlusion 
are important considerations. Patients who are Child-Pugh 
A with an ECOG performance status of 0 and receiving 
intra-arterial therapy have superior survival to those with 
Child-Pugh B/C disease or any ECOG limitations (66). 
There is also a difference in outcomes when SIRT is 
used in patients with segmental/lobar PVT versus main 
PVT. Kulik et al. reported toxicities and outcomes in 
108 patients with no PVT (n=71), segmental/lobar PVT 
(n=25) and main PVT (n=12) (67). Median survival for 
the three groups was 467, 304, and 134 days, respectively. 
Similar dosimetry was used for all patients. In general, 
SIRT was well tolerated with limited liver toxicity. There 
were no differences in the level of PVT and changes in 
A B C
D E F
Figure 5 Y-90 SIRT for BCLC C hepatocellular carcinoma. This 60-year-old female with chronic hepatitis C was imaged after she had 
elevated liver function tests during a routine physical examination. Magnetic resonance imaging demonstrated an 8.7 cm right posterior 
(A) and smaller satellite nodule more inferiorly (B). The right portal vein was thrombosed and distended with tumor (white arrow, C), 
while the main and left portal veins remained patent (black arrow, C). At a multidisciplinary tumor board, the group decision was made to 
treat with intra-arterial therapy and to reserve sorafenib for metastatic disease should it develop at a later time. Angiography demonstrated 
the extensive tumor occupying most of the right lobe (D). Two months after treatment, there was remarkable reduction in tumor size and 
enhancement burden, with a small residual inferior nodule most notable (arrow, E). Three months later, the tumor thrombus had also 
decreased in size and the right portal vein had partially recanalized (arrow, F). Y-90, yttrium 90; SIRT, selective internal radiation therapy; 
BCLC, Barcelona clinic liver cancer.
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hepatic encephalopathy or total bilirubin. New ascites 
was an AE significantly more common with main PVT 
(55%) compared with no PVT (15%) or segmental/lobar 
PVT (5%). In 41 patients with HCC and PVT (68) the 
injected activity of SIRT was adjusted upward when there 
was increased tumor-to-normal-liver uptake on mapping 
scintigraphy. Patients with high tumor-to-normal liver 
ratios receiving 205 Gy or more had superior outcomes 
compared with patients who received a dose of less than 
205 Gy. OS was 12 months with main PVT and 22 months 
with segmental/lobar PVT. The ability to deliver doses 
up to 205 Gy was limited in some cases by the non-tumor 
liver dose or hepatopulmonary shunting. HCC and portal 
vein invasion are both associated with increased pulmonary 
shunting (69). HCC had a median and upper value lung 
shunt fraction of 11.7% and 39.4%, respectively, while 
PVT averaged 15.8%, with a maximal value of 31.2%. 
In the setting of HCC with PVT, the mean lung shunt 
fraction was 16.6%, with a maximum of 31%. 
Clinical question 6: HCC or metastatic disease patient 
receiving immunotherapy
What  i s  the  ra t iona le  for  combin ing  SIRT and 
immunotherapy in a patient with HCC or metastatic disease 
such as colorectal adenocarcinoma and unresectable liver 
metastases, who has failed standard chemotherapy?
Rationale and recommendations
Radiation treatment has remarkable immunomodulatory 
effects (70). Promotion and suppression of tumor-
specific immunity have been described in association 
with radiotherapy, and depend on whether the elicited 
inflammation is acute or chronic. Acute inflammation is a 
potent stimulator of anti-tumor immunity through a variety 
of mechanisms, including activation of tumor-associated 
dendritic cells (71), expression of cancer-testis (CT) and 
MHC class I antigens on the tumor surface (72), and tumor 
infiltration by CD8+ T cells (73). Promotion of anti-tumor 
immunity in the context of acute inflammation is critically 
dependent upon transient complement activation involving 
local production of C3a and C5a anaphylatoxins (74). 
Indeed, blocking complement activation via administration 
of glucocorticoids drastically reduces radiotherapy-
mediated anti-tumor immune effects (74). In contrast to 
acute inflammation, chronic inflammation is known to 
promote development of a tumor-permissive, tolerogenic 
microenvironment (75), involving immune suppressor 
cells (76,77) and, potentially, alternatively (M2) activated 
macrophages, immune suppressive cytokines and checkpoint 
upregulation. 
Different therapeutic radiation modalities may trigger 
distinct inflammatory responses. A 14-day long, continuous 
intrahepatic radiation delivery by SIRT may elicit a 
prevalently suppressive, chronic inflammation. In addition, 
continuous exposure to radiation may exert deleterious 
effects on rapidly proliferating, radiosensitive T cells 
infiltrating the tumor. Not surprisingly, SIRT resulted in 
an early (24 h), profound (>50%) and prolonged (up to 
30 months) lymphopenia in a study enrolling 92 HCC 
patients, and delayed recovery of T and B lymphocytes 
was associated with a poor prognosis (78). Moreover, 
increased neutrophil-to-lymphocyte (NTL) and platelet-to-
lymphocyte (PTL) ratios were observed in patient receiving 
SIRT, and found to be associated with worse clinical 
outcome (79).
The use of SIRT in combination with immunotherapy 
has only recently begun to be investigated. Ongoing 
clinical trials are exploring SIRT in combination with 
CAR-T hepatic artery infusion for carcinoembryonic 
antigen (CEA)-expressing liver metastases (ClinicalTrials.
gov ID: NCT02416466), with nivolumab in a phase 
II single-center recruiting Asian patients with HCC 
(ClinicalTrials.gov ID: NCT03033446), with concurrent 
ipilimumab and nivolumab in uveal melanoma with liver 
metastases (ClinicalTrials.gov ID: NCT02913417), and 
with durvalumab and tremelimumab in patients with liver-
predominant mCRC and microsatellite-stable disease 
(ClinicalTrials.gov ID: NCT03005002).
Therefore, it is not possible to formulate evidence-based 
recommendations on SIRT-immunotherapy combinatorial 
approaches. Immunotherapy could counter immune 
suppression due to chronic inflammation and continuous 
radiation. Hence, adoptive transfer of autologous (including 
CAR-engineered) lymphocytes, checkpoint blockade 
inhibitors and tumor-associated antigen targeting might 
result in improved clinical outcomes. Delivery of concurrent 
stereotactic, hypofractionated high-dose irradiation may 




The scheduled follow-up visit following SIRT should be 
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2 weeks after the procedure, with most teams performing 
additional evaluations at 4 or 6 weeks, and again at 12 weeks 
post-SIRT. At these visits, a physical examination, complete 
blood count, and liver function tests are a minimum to 
inform on safety of ongoing treatments. Data from a variety 
of experiences demonstrate optimal radiological response to 
treatment at 12 weeks post SIRT.
SIRT and surgery
SIRT may downsize tumors to allow resection (80-84), or 
be a bridge to liver transplantation and for down-staging 
HCC before transplantation (85-87). In addition, SIRT 
can produce concomitant hypertrophy in the contralateral 
lobe (88), a phenomenon that occurs in approximately 26% 
to 47% of patients after between 44 days and 9 months (88). 
Although not the primary objective of the SIRT procedure, 
contralateral hypertrophy represents a potential benefit 
for patients who subsequently undergo hepatic resection. 
However, it is important to consider the feasibility and 
safety of surgery after SIRT, and to determine the impact 
of concomitant chemotherapy. A preliminary study of 
13 patients who underwent SIRT followed by lobectomy 
found the approach to be an effective method to induce 
hypertrophy of the future liver remnant (FLR) prior to 
resection (89). The median time to resection in this study 
was 86 days (30–210 days); and with PVE the median 
time to resection was 37 days (21–84 days) (90). The P4S 
study may help formulate guidance on the practicalities 
and safety of surgery after SIRT (91). In this study of 100 
patients undergoing liver surgery after receiving SIRT, 
mortality and complication rates appeared acceptable 
given the risk profile of the recruited patients (91). 
Resection after SIRT appears to be safe even for major 
resections, and in cirrhotic and non-cirrhotic patients. 
Generally, preserving the future liver remnant from 
radiation is recommended for patients with borderline 
resectability. However, recommendations on timing and 
other considerations are not possible at this time.
Treatment combinations in other tumors
SIRT can be used for other solid tumors, and it is important 
to consider the therapeutic agents that such patients have 
received, the total duration of systemic agent use, agents 
they are currently receiving, and the possible interactions 
these agents may have with SIRT (Table 1).
ICC
Several prospective and retrospective studies have assessed 
SIRT in ICC (all second- or later-line), which demonstrate 
median OS of between 9.3 and 22 months (19,92-100). A 
pooled analysis of 12 studies, with a total of 298 patients 
with unresectable ICC treated with SIRT, demonstrated a 
median OS of 15.5 months and treatment response rate of 
28% (101). However, these studies provide little guidance 
on possible interactions with other therapies. A common 
chemotherapy for ICC is the radiosensitizer gemcitabine 
and possible interactions between this agent and SIRT 
need to be considered (102). The radiosensitizing effects of 
gemcitabine can last several weeks, and so it may be prudent 
to stop gemcitabine therapy 4–8 weeks before SIRT [if there 
is a risk of tumor progression during this period, second-line 
chemotherapy (e.g., with FOLFOX) can be started during 
this phase)]. After SIRT, a delay of a minimum of 2 weeks 
before initiating gemcitabine is advisable until further data 
emerge. In the ongoing SIRCCA trial, systemic cisplatin-
gemcitabine chemotherapy is being administered 14–16 days 
after SIRT (ClinicalTrials.gov ID: NCT02807181). 
Pancreatic (exocrine) cancer
A prospective phase II study of SIRT and systemic 
chemotherapy in liver-dominant metastatic pancreatic 
adenocarcinoma concluded that the approach appeared 
to be effective, and is likely to be of most benefit in 
those patients with a resected primary tumor and liver-
only disease (24). Importantly, patients who received 
gemcitabine at least 8 weeks after the SIRT procedure 
had a similar rate of AEs to the expected rates with 
gemcitabine alone. There was no evidence of REILD, 
which suggests that it is acceptable to treat patients with 
gemcitabine after SIRT. 
Metastatic breast cancer
The data on SIRT use in liver metastases from breast cancer 
are from both prospective and retrospective series from 
single centers. Although these studies all showed positive 
results with SIRT in this setting, none reported on the 
combination of SIRT with other therapies (10,103-108). 
Experienced SIRT teams regularly treating breast cancer 
metastases advise caution in total activity delivered in those 
patients with several years of chemotherapy exposure. 
Hepatic tolerance to SIRT is sometimes lower in this 
situation than in mCRC. Unpublished modification of 
standard approaches among these teams includes sequential 
lobar SIRT, empiric reduction of total activity by 25%, 
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and consideration of concurrent use of ursodiol and 
methylprednisolone as is recommended in HCC patients at 
high-risk for REILD.
NETs
The NCCN, North American Neuroendocrine Tumor 
Society (NANETS) and European Neuroendocrine Tumor 
Society (ENETS) guidelines all recommend embolization for 
symptomatic or progressive neuroendocrine liver metastases 
refractory to somatostatin receptor blockade, without 
preference among the embolization techniques (109-111). 
Several studies have investigated the use of SIRT for NETs 
as first-line in treatment-refractory disease or as salvage 
therapy (20,21,112-115). These studies include concurrent 
use of somatostatin analogs, and no specific issues have been 
reported with this combination. A systematic analysis of 
12 series encompassing 423 patients found widely variable 
objective, clinical and biochemical response rates (116). 
The few series with long-term follow-up reported 2- and 
5-year survival ranging from 57% to 69% and from 45% 
to 55%, respectively. There appears to be little difference 
in the relative benefits of SIRT and other embolization 
techniques (117), but the quality and strength of the data do 
not allow firm conclusions (29). Nevertheless, SIRT may 
cause fewer side-effects and requires fewer treatments than 
chemoembolization techniques. Nearly all the patients in the 
studies reviewed were concurrently receiving octreotide or 
other somatostatin analog at the time of SIRT.
SIRT has been used in patients with NET receiving 5FU 
(20,113,118). For example, SIRT has been given with a 7-day 
systemic infusion of 5FU in 34 patients with progressive 
unresectable NET liver metastasis (118). As this combination 
is used widely in mCRC, the same safety considerations 
apply. A commonly applied systemic approach to metastatic 
NETs is an oral combination regimen of capecitabine and 
temozolomide (CapTem), which alone has a 60% objective 
response rate for well-differentiated NETs (119). A feasibility 
and safety study of integrated CapTem and SIRT delivered 
on day 7 of the 14-day cycle, demonstrated no worse than 
additive toxicities, with better than expected disease control 
in the liver, suggesting a synergy justifying expansion into a 
phase II trial (120).
The imminent introduction of PRRT in the USA raises 
questions about both sequencing and tolerance of systemic 
and liver-directed radiotherapies. Limited retrospective 
data demonstrated no significant toxicity when giving SIRT 
in NET patients who had received PRRT, suggesting that 
radiation exposure by PRRT may not cause significant 
toxicity in subsequent SIRT (121). Conversely, patients 
who undergo PRRT following prior liver-directed therapies 
derive less benefit, while sustaining higher rates of liver, 
renal and marrow toxicities (122). Another concern 
is the growing recognition of late radiation-induced 
hepatotoxicity following SIRT in long-lived NET patients, 
particularly when other therapeutic options include 
potentially hepatotoxic agents (123,124).
The targeted agents everolimus (mTOR inhibitor) and 
sunitinib (a receptor TKI) are both approved for NETs 
based on improved PFS in controlled trials. There is 
no data suggesting harm or benefit in combining these 
biological agents with SIRT.
Retreatment with SIRT
When SIRT has been effective and either new tumor 
appears in the previously treated liver or persistent hepatic 
tumor is increasing, a second (or more) application(s) 
of SIRT is a reasonable consideration. It is beyond the 
scope of this paper to discuss the wealth of supportive 
data showing safety and efficacy of subsequent treatments 
of SIRT; however, the timing of a second SIRT should 
be considered. Provided the patient is otherwise eligible 
for SIRT using standard criteria, a separation of 90 days 
between SIRT treatments is typically recommended. This 
is due to the risk of REILD, which can have a latency of 
up to 90 days. 
If the original treatment was to only one hepatic lobe, 
and the new SIRT is to the previously untreated hepatic 
lobe, no delay is required, as this would not be considered 
‘retreatment’. 
Conclusions
	 SIRT appears to be safely integrated into the 
pathways of the standard of care for most tumor 
types, however level 1 evidence is lacking except for 
first-line use in mCRC;
	 While precautions need to be taken with certain 
drugs such as VEGF inhibitors and gemcitabine, 
in general, there are no reported specific toxicities 
indicating a need to withhold other agents in order 
to perform SIRT;
	 Data on combining SIRT with 5FU or with FOLFOX 
(in large phase III trials) are reassuring but caution 
is still required when combining SIRT with other 
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chemotherapy regimens in the salvage setting;
	 Continuous tumor radiation delivered by SIRT may 
have immunosuppressive effects. Combining immune 
checkpoint inhibition or T cell therapy with SIRT 
could potentially result in improved clinical outcomes, 
a hypothesis being tested by ongoing clinical trials. 
Targeted radiosurgery of an index lesion in combination 
with SIRT may induce immune stimulation.
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